Human Molecular Genetics · 2012 · 55 citations · 42 references
Life SciencesGeneticsNeuroscienceEpigeneticsGene ExpressionNeurogeneticsEpigenetic Regulation In NeurodegenerationEpigenetic Regulation In NeuronsMolecular NeurogeneticsSpinal Muscular AtrophyDifferential Protein Expression AnalysisInduced Pluripotent Stem Cell ModelsInduced Pluripotent Stem CellsMicroarray AnalysisMicroarray Differential Expression AnalysisShort-chain Fatty Acid TherapySpinal Muscular Atrophy PharmacotherapyValproic Acid
Functional loss of SMN1 causes proximal spinal muscular atrophy (SMA), the most common genetic condition accounting for infant lethality. Hence, the hypomorphic copy gene SMN2 is the only resource of functional SMN protein in SMA patients and influences SMA severity in a dose-dependent manner. Consequently, current therapeutic approaches focus on SMN2. Histone deacetylase inhibitors (HDACi), such as the short chain fatty acid VPA (valproic acid), ameliorate the SMA phenotype by activating the SMN2 expression. By analyzing blood SMN2 expression in 16 VPA-treated SMA patients, about one-third of individuals were identified as positive responders presenting increased SMN2 transcript levels. In 66% of enrolled patients, a concordant response was detected in the respective fibroblasts. Most importantly, by taking the detour of reprograming SMA patients' fibroblasts, we showed that the VPA response was maintained even in GABAergic neurons derived from induced pluripotent stem cells (iPS) cells. Differential expression microarray analysis revealed a complete lack of response to VPA in non-responders, which was associated with an increased expression of the fatty acid translocase CD36. The pivotal role of CD36 as the cause of non-responsiveness was proven in various in vitro approaches. Most importantly, knockdown of CD36 in SMA fibroblasts converted non- into pos-responders. In summary, the concordant response from blood to the central nervous system (CNS) to VPA may allow selection of pos-responders prior to therapy. Increased CD36 expression accounts for VPA non-responsiveness. These findings may be essential not only for SMA but also for other diseases such as epilepsy or migraine frequently treated with VPA.
42
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Kazutoshi Takahashi, Koji Tanabe, Mari Ohnuki et al. · Cell · 2007 · 20.2K citations
Induced pluripotent stem cells from a spinal muscular atrophy patient
Allison D. Ebert, Junying Yu, Ferrill F. Rose et al. · Nature · 2008 · 1.4K citations · Full text
CD36 is a receptor for oxidized low density lipoprotein
Gerda Endemann, Lawrence W. Stanton, Kelley S. Madden et al. · Journal of Biological Chemistry · 1993 · 1.3K citations · Full text